NASDAQ : COLL
Collegium Pharmaceutical, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 23.8 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 774.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 773.20M |
| Enterprise Value | 1.86B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 32.56M |
| Shares Outstanding | 32.56M |
| Shares Change (YoY) | -9.08% |
| Shares Change (QoQ) | -18.98% |
| Owned by Insiders (%) | 1.12% |
| Owned by Institutions (%) | 119.10% |
| Float | 29.77M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 16.90 |
| Forward PE | 3.36 |
| PS Ratio | 0.96 |
| Forward PS | 0.92 |
| PB Ratio | 2.48 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 2.36 |
| P/OCF Ratio | 2.35 |
| PEG Ratio | 0.67 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 38.87 |
| EV / Sales | 2.30 |
| EV / EBITDA | 4.60 |
| EV / EBIT | 10.85 |
| EV / FCF | 5.67 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.03 |
| Quick Ratio | 0.70 |
| Debt / Equity | 3.90 |
| Debt / EBITDA | 2.95 |
| Debt / FCF | 3.71 |
| Interest Coverage | 2.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 17.61% |
| Return on Assets (ROA) | 5.75% |
| Return on Invested Capital (ROIC) | 9.54% |
| Return on Capital Employed (ROCE) | 11.10% |
| Weighted Average Cost of Capital (WACC) | 5.58% |
| Revenue Per Employee | $1.91M |
| Profits Per Employee | $113,274 |
| Employee Count | 423 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.13 |
Taxes
| Measure | Value |
|---|
| Income Tax | 29.77M |
| Effective Tax Rate | 38.32% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -33.94% |
| 50-Day Moving Average | 23.23 |
| 200-Day Moving Average | 33.12 |
| Relative Strength Index (RSI) | 56.64 |
| Average Volume (20 Days) | 605,916 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.38M |
| Short Previous Month | 5.52M |
| Short % of Shares Out | 16.51% |
| Short % of Float | 18.06% |
| Short Ratio (days to cover) | 6.36 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 808.21M |
| Gross Profit | 722.93M |
| Operating Income | 171.65M |
| Pretax Income | 77.68M |
| Net Income | 47.92M |
| EBITDA | 405.26M |
| EBIT | 171.65M |
| Earnings Per Share (EPS) | $1.41 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 129.47M |
| Total Debt | 1.22B |
| Net Cash | -1.09B |
| Net Cash Per Share | -$33.43 |
| Equity (Book Value) | 311.91M |
| Book Value Per Share | 9.60 |
| Working Capital | 18.15M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 329.92M |
| Capital Expenditures | -1.64M |
| Depreciation & Amortization | 233.60M |
| Net Borrowing | 246.91M |
| Free Cash Flow | 328.28M |
| FCF Per Share | $10.08 |
Margins
| Measure | Value |
|---|
| Gross Margin | 89.45% |
| Operating Margin | 21.24% |
| Pretax Margin | 9.61% |
| Profit Margin | 5.93% |
| EBITDA Margin | 50.14% |
| EBIT Margin | 21.24% |
| FCF Margin | 40.62% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 9.08% |
| Shareholder Yield | 9.08% |
| Earnings Yield | 5.92% |
| FCF Yield | 42.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $49.00 |
| Price Target Difference | 106.32% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 2.84% |
| EPS Growth Forecast (3Y) | 0.42% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.99 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |